PYC - General Discussion, page-589

Hi Ladytrader,
It looks like a day for blue sky predictions. Before I start I should say. I find actionnaires assessment a pretty realistic one. A price I feel that most on this forum would be happy with some time next year. I also don’t discount what you are saying. In general I would say estimating share price at a time point isn’t my strength. I do find on these forums that if too many bluesky predictions are touted it creates a lot of disenchanted posters when the realities of being an early stage biotech kick in.

So anyway since we are talking blue sky I’ll tell you mine without any numbers apologies to the crunchers. So why is this company different to the other biotechs I hold in my view? I have at least one other that has 4 phase II trials that I really believe in.

To use an analogy this company is like sitting in a dark room it’s daylight outside and there is a small hole letting light in. You look at the light and see clinical/preclinical trials with a huge revenue potential. You see there is a high likelihood of success because of the trial design and the section of biotech it is in.

As you move a bit closer you start to see a bit more of the light. The cell penetrating peptides solve potential toxicity of RNA drugs. Does this give the company a competitive advantage or can it be sold to others developing RNA therapies? You see that one of the drugs is involved in enhancing mitochondrial function and there are other conditions in the eye which may have poor mitochondrial function including the huge population that have glaucoma leading to multiple phase II trials potential from 1 drug.

You move a bit closer. There are other conditions that have mitochondrial dysfunction elsewhere in the body. Could this drug be of help? There are around 6000 similar single gene mutation diseases (Mentioned in one of the presentations that is from memory and numbers don’t always stick with me feel free to check). Potential targets for similar drugs.

As you put your eye right up to the peephole you see a beautiful sunny day, blue sky mountains and a lake. Once you have access to the cell what can you do with RNA modifying drugs. (My biotech knowledge is well out of date now but) The potential is huge not just amplifying protein production, decreasing production skipping sections that are faulty. Single gene mutations are only the low hanging fruit. There are numerous other genetic diseases. Then what about diseases that aren’t necessarily genetic but over or underproduce a certain protein? With a fraction of the revenue from our current drugs under development what could we do?

Anyway, I’m still sitting in a dark room, looking at a spot of light. It’s dark and someone has left a lot of obstacles in the way we have to negotiate. I’ll be extremely happy with $1.35 sometime next year and try not to think too much about the view from the peephole. It’s rude to peep right?

Eagle